Kodiak Sciences Inc.
NASDAQ:KODBiotechnology
-$0.03 today
- Market cap
- $6.40B
- Beta
- 2.21
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$3.73
Volume 0.74M
Average 1.10M
KOD EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Kodiak Sciences Inc.NASDAQ: KOD
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$66.22M, compared with -$54.92M a year earlier. Trailing-twelve-month EBITDA was -$225.15M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -36.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$66.22M-9.3% QoQ
- Last fiscal yearDec 2025
- -$203.65M-36.2% YoY
- LTMSep 2026
- -$225.15M-18.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -20.6% | +100.0% | +120.6 pp |
| 1 year | -36.2% | +100.0% | +136.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (203.65M) USD
- Year-over-year change
- -36.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (203.65M) | -36.2% |
| FY2024 | 2024-12-31 | (149.5M) | +36.3% |
| FY2023 | 2023-12-31 | (234.53M) | +27.3% |
| FY2022 | 2022-12-31 | (322.8M) | -25.0% |
| FY2021 | 2021-12-31 | (258.26M) | — |
EBITDA vs competitors
How KOD compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -18.0% is the 5th highest of 10, against a peer median of -19.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.75B USD | +6.1% | +3.4% | 37.0% | |
| LTM Jun 2026 | $742M USD | +61.3% | -3.6% | 13.9% | |
| LTM Mar 2026 | -$62.08M USD | -482.8% | — | 18634.1% | |
| LTM Mar 2026 | -$64.18M USD | -19.1% | — | 1437.5% | |
| LTM Mar 2026 | -CHF 94.13M CHF | +7.5% | — | 18676.3% | |
BLTEBelite Bio, Inc | LTM Sep 2026 | -$129.44M USD | -116.5% | — | — |
| LTM Mar 2026 | -$163.43M USD | +3.9% | — | 185.2% | |
| LTM Sep 2026 | -$225.15M USD | -18.0% | — | — | |
| LTM Mar 2026 | -$260.06M USD | -79.4% | — | 3415.1% | |
| LTM Mar 2026 | -$274.24M USD | -55.5% | — | 527.0% | |
| Peer median (excluding KOD) | — | -19.1% | -0.1% | 982.2% | |
Competitors are the stored peer set for KOD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 8.71M | 11M | 25.95M | 26.71M | 0 |
| Gross Profit | (8.71M) | (11M) | (25.95M) | (26.71M) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 217.34M | 267.59M | 206.3M | 126.1M | 182.37M |
| Selling, General & Admin | 41M | 62.79M | 71.02M | 34.05M | 52.02M |
| Operating Expenses | 258.34M | 330.38M | 251.37M | 160.14M | 234.39M |
| Depreciation & Amortization | 8.71M | 11M | 25.95M | 26.71M | 26.32M |
| EBITDA | (258.26M) | (322.8M) | (234.53M) | (149.5M) | (203.65M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (267.05M) | (341.38M) | (277.32M) | (186.85M) | (234.39M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 298K | 7.07M | 16.73M | 11.15M | 4.52M |
| Interest Expense | 22K | 18K | 13K | 0 | 0 |
| Other Income / Expenses | 61K | 7.56M | 16.83M | 10.64M | 4.42M |
| Income Before Tax | (266.99M) | (333.82M) | (260.49M) | (176.21M) | (229.97M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (266.99M) | (333.82M) | (260.49M) | (176.21M) | (229.97M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (5.16) | (6.39) | (4.97) | (3.35) | (4.32) |
| EPS (Diluted) | (5.16) | (6.39) | (4.97) | (3.35) | (4.32) |
| Weighted Avg Shares | 51.79M | 52.25M | 52.41M | 52.58M | 53.21M |
| Weighted Avg Shares (Diluted) | 51.79M | 52.25M | 52.41M | 52.58M | 53.21M |
Kodiak Sciences Inc.
NASDAQ:KOD
Intrinsic Alpha fair value
Locked
Current Price
$97.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.